CRISPR-engineered T cells in patients with refractory cancer

• DOI: 10.1126/science.aba7365
• Publication Date: 2020-02-07T00:09:20Z
• Authors: Edward A. Stadtmauer; Joseph A. Fraietta; Megan M. Davis; Adam D. Cohen; Kristy L. Weber; Eric Lancaster; Patricia A. Mangan; Irina Kulikovskaya; Minnal Gupta; Fang Chen; Lifeng Tian; Vanessa E. Gonzalez; Jun Xu; In-young Jung; J. Joseph Melenhorst; Gabriela Plesa; Joanne Shea; Tina Matlawski; Amanda Cervini; Avery L. Gaymon; Stephanie Desjardins; Anne Lamontagne; January Salas-Mckee; Andrew Fesnak; Donald L. Siegel; Bruce L. Levine; Julie K. Jadlowsky; Regina M. Young; Anne Chew; Wei-Ting Hwang; Elizabeth O. Hexner; Beatriz M. Carreno; Christopher L. No...; Frederic D. Bushman; Kevin R. Parker; Yanyan Qi; Ansuman T. Satpathy; Howard Y. Chang; Yangbing Zhao; Simon F. Lacey; Carl H. June
• Keywords: Multiplex

CRISPR-Cas9 gene editing provides a powerful tool to enhance the natural ability of human T cells fight cancer. We report first-in-human phase 1 clinical trial test safety and feasibility multiplex engineer in three patients with refractory Two genes encoding endogenous cell receptor (TCR) chains, TCRα (